Moderna to build UK’s first mRNA vaccine research and manufacturing centre

US biotech firm agrees £1bn deal with government for centre to combat Covid and other illnesses

The Boston-based biotech Moderna is to build the UK’s first research and manufacturing centre dedicated to the development of mRNA vaccines against new Covid variants and other respiratory illnesses, in an effort to improve readiness for future pandemics.

Under a £1bn deal with the UK government, construction of the new centre – Moderna’s first facility in Britain – could begin later this year and is expected to start producing the first shots in 2025. The government has committed to buying Moderna’s vaccines for the next decade.

The jabs are based on messenger RNA, the molecule that teaches our cells to make specific proteins that will trigger an immune response inside our bodies. Moderna developed one of two mRNA vaccines used worldwide against Covid-19, the other being produced by Germany’s BioNTech and US firm Pfizer.

Moderna’s chief executive, Stéphane Bancel, said the priority was to develop a jab combining boosters against Covid, flu and respiratory syncytial virus (RSV). RSV usually causes mild, cold-like symptoms but can be serious for infants and older people.

MRNA technology proved one of the fastest routes to produce an effective vaccine against Covid, and scientists are exploring its use against other diseases, such as cancer, heart disease, flu and malaria.

The daily Business Today email or follow Guardian Business on Twitter at @BusinessDesk

Boris Johnson said the investment would “guarantee jabs in arms against some of the toughest viruses out there, bringing us to the forefront of the fight against future threats”. He added: “We’ve all seen what vaccines can do, and today’s partnership brings us one step closer to finding cures for some of the most devastating diseases.”

The health secretary, Sajid Javid, added: “Our new partnership with Moderna will cement the UK’s status as a science superpower, significantly boosting the economy and creating jobs and it has the potential to unlock the next generation of cutting-edge vaccines to fight diseases such as Covid, seasonal flu and RSV.”

Moderna said it planned to expand its presence in the UK through investments in R&D and promised deliver a large share of its clinical trials in the UK.

Separately, Moderna said it plans to apply within days to US and UK regulators for approval for its new two-strain Covid-19 vaccine. The company released data to show the vaccine, called mRNA1273.214, protects against the Omicron strains BA.4 and BA.5, which are driving a current surge of cases. The new vaccine combines 25 micrograms of the original Moderna Covid vaccine with 25 micrograms of vaccine specifically targeted at the Omicron variant.

Dr Paul Burton, Moderna’s chief medical officer, said the company is ready to deliver the vaccine for booster programmes as early as August. Relying on vaccines based on the original Covid strain for autumn booster programmes will result in “a shorter duration of protection, less robust protection and more severe disease and hospitalisation”, Burton said.


Julia Kollewe

The GuardianTramp

Related Content

Article image
India’s Poonawalla family donate £50m for Oxford vaccine centre
Billionaire family own and run world’s largest vaccine producer, Serum Institute of India

Rupert Neate Wealth correspondent

15, Dec, 2021 @1:10 PM

Article image
Moderna forecasts $18bn in sales of Covid vaccine this year
Better than expected revenues will push US firm founded in 2010 into profit for first time

Julia Kollewe

25, Feb, 2021 @6:14 PM

Article image
From Pfizer to Moderna: who's making billions from Covid-19 vaccines?
The companies in line for the biggest windfalls – and the shareholders who have already made fortunes

Julia Kollewe

06, Mar, 2021 @11:55 AM

Article image
'Vaccine prince': the Indian billionaire set to make Covid jabs for the UK
Serum Institute boss Adar Poonawalla has rented a Mayfair mansion for £50,000 a week

Rupert NeateWealth correspondent

27, Mar, 2021 @8:00 AM

Article image
AstraZeneca could supply potential coronavirus vaccine from September
Firm has capacity to make 1bn doses of Oxford University drug undergoing trials

Staff and agencies

21, May, 2020 @12:08 PM

Article image
Members of vaccine taskforce to be reassigned to HRT crisis
Sajid Javid announces move after emergency meeting with manufacturers and pharmacists

Julia Kollewe

05, May, 2022 @5:35 PM

Article image
UK cancels Covid vaccine deal with French firm Valneva
Government serves notice to terminate contract over allegations of a ‘breach of obligations’

Jamie Grierson and Rob Davies

13, Sep, 2021 @12:35 PM

Article image
Pfizer forecasts $26bn from annual sales of Covid-19 vaccine
Vaccine will generate 73% more than forecast based on contracts signed until mid-April

Julia Kollewe

04, May, 2021 @1:12 PM

Article image
Johnson’s scapegoating the young over Covid jabs is not a wise tactic | Larry Elliott
If the Conservatives want to win the hearts and minds of the under-25s they’d do better by incentivising vaccination

Larry Elliott

01, Aug, 2021 @11:09 AM

Article image
Vaccines were not part of AstraZeneca’s grand strategy, so what’s the plan now?
Having built a big operation during the pandemic it could stick or twist but either way investors will soon want a decision

Nils Pratley

15, Jun, 2021 @6:40 PM